Rhodiola rosea extract
Rhodiola rosea (salidroside / rosavins) · also known as Rhodiola, Salidroside, Rosavins, Salidroside
Rhodiola rosea extract is classed as an adaptogenic herb. A randomized trial in 60 people showed that a specific extract can lower the cortisol response after waking. It inhibits monoamine oxidase (MAO) in vitro, but there is not enough human evidence that usual oral doses inhibit MAO in the brain.
Clinical uses and human evidence
Fatigue and energy
Studies (2)
- Olsson 2009 · Planta Med · RCT · n=60 — A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract shr-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue
- Ishaque 2012 · BMC Complement Altern Med · systematic review — Rhodiola rosea for physical and mental fatigue: a systematic review
Low mood
Endurance performance
Studies (2)
- Wang 2025 · Front Nutr · meta-analysis · n=668 — The effect of Rhodiola rosea supplementation on endurance performance and related biomarkers: a systematic review and meta-analysis
- Sanz-Barrio 2023 · Phytother Res · systematic review · n=263 — Rhodiola rosea supplementation on sports performance: A systematic review of randomized controlled trials
Anxiety and stress
Mechanisms of action
Hypothalamic-pituitary-adrenal (HPA) axis blunting and cortisol stress buffering
In a 60-person randomized controlled trial, 576 mg/day of a specific extract for 28 days produced a between-group difference in the salivary cortisol awakening response, measured directly in humans. This does not show that ACTH, receptor sensitivity or Hsp70 are also regulated. The trial dose was slightly higher than usual, and the result should not be generalized to all extracts.
Monoamine neurotransmitter balance (dopamine, norepinephrine, 5-HT)
Rhodiola extract and its components showed inhibitory activity in a recombinant human MAO system, an in-vitro result. Extract composition and pharmacokinetics vary considerably, and in-vitro inhibition does not show that effective concentrations are reached in the brain. There is also no reliable evidence that usual oral doses inhibit MAO in the human brain or change monoamine turnover.
Safety and drug interactions
Serotonin excess risk
Has a weak MAO-inhibiting effect. Each of these raises serotonin levels in the brain. Taking two or more together carries a risk of serotonin syndrome, which causes agitation, sweating, a fast heartbeat, muscle twitching and fever. In severe cases it can be life-threatening.
With SSRIs, SNRIs and other serotonergic drugs Needs attention
Has weak MAO-inhibiting activity; use together with caution.
With MAO inhibitors Needs attention
Has weak MAO-inhibiting activity; use with caution alongside MAOIs.